Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities » 10:10
01/15/21
01/15
10:10
01/15/21
10:10
ARCT

Arcturus Therapeutics

$65.00 /

+2.67 (+4.28%)

, JNJ

Johnson & Johnson

$160.15 /

-0.5 (-0.31%)

B. Riley Securities…

B. Riley Securities analyst Mayank Mamtani downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy with a price target of $77, down from $138, after Johnson & Johnson (JNJ) released what Mamtani called "compelling" Phase I/II immunogenicity data on its COVID-19 vaccine candidate, Ad26. J&J's data exceeded Street expectations, particularly on neutralizing antibody responses, according to Mamtani, who thinks the results raise the uncertainty about ARCT-021's path to "being a formidable C-19 vaccine player."

ShowHide Related Items >><<
JNJ Johnson & Johnson
$160.15 /

-0.5 (-0.31%)

ARCT Arcturus Therapeutics
$65.00 /

+2.67 (+4.28%)

ARCT Arcturus Therapeutics
$65.00 /

+2.67 (+4.28%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Wells Fargo
Arcturus Therapeutics initiated with an Overweight at Wells Fargo
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
JNJ Johnson & Johnson
$160.15 /

-0.5 (-0.31%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
12/15/20 Goldman Sachs
Medtronic upgraded to Neutral from Sell at Goldman Sachs
JNJ Johnson & Johnson
$160.15 /

-0.5 (-0.31%)

ARCT Arcturus Therapeutics
$65.00 /

+2.67 (+4.28%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
JNJ Johnson & Johnson
$160.15 /

-0.5 (-0.31%)

ARCT Arcturus Therapeutics
$65.00 /

+2.67 (+4.28%)

JNJ Johnson & Johnson
$160.15 /

-0.5 (-0.31%)

ARCT Arcturus Therapeutics
$65.00 /

+2.67 (+4.28%)

JNJ Johnson & Johnson
$160.15 /

-0.5 (-0.31%)

ARCT Arcturus Therapeutics
$65.00 /

+2.67 (+4.28%)

Options
Arcturus Therapeutics call volume above normal and directionally bullish » 13:05
01/08/21
01/08
13:05
01/08/21
13:05
ARCT

Arcturus Therapeutics

$73.57 /

+6.72 (+10.05%)

Bullish option flow…

Bullish option flow detected in Arcturus Therapeutics with 16,904 calls trading, 6x expected, and implied vol increasing almost 21 points to 139.03%. Feb-21 60 calls and Jan-21 55 calls are the most active options, with total volume in those strikes near 4,400 contracts. The Put/Call Ratio is 0.19. Earnings are expected on March 11th.

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$73.57 /

+6.72 (+10.05%)

ARCT Arcturus Therapeutics
$73.57 /

+6.72 (+10.05%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Wells Fargo
Arcturus Therapeutics initiated with an Overweight at Wells Fargo
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
ARCT Arcturus Therapeutics
$73.57 /

+6.72 (+10.05%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
ARCT Arcturus Therapeutics
$73.57 /

+6.72 (+10.05%)

ARCT Arcturus Therapeutics
$73.57 /

+6.72 (+10.05%)

ARCT Arcturus Therapeutics
$73.57 /

+6.72 (+10.05%)

Options
Arcturus Therapeutics call volume above normal and directionally bullish » 14:45
01/07/21
01/07
14:45
01/07/21
14:45
ARCT

Arcturus Therapeutics

$67.59 /

+18.23 (+36.93%)

Bullish option flow…

Bullish option flow detected in Arcturus Therapeutics with 17,453 calls trading, 6x expected, and implied vol increasing over 6 points to 121.15%. Jan-21 70 calls and Jan-21 60 calls are the most active options, with total volume in those strikes near 5,000 contracts. The Put/Call Ratio is 0.24. Earnings are expected on March 11th.

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$67.59 /

+18.23 (+36.93%)

ARCT Arcturus Therapeutics
$67.59 /

+18.23 (+36.93%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Wells Fargo
Arcturus Therapeutics initiated with an Overweight at Wells Fargo
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
ARCT Arcturus Therapeutics
$67.59 /

+18.23 (+36.93%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
ARCT Arcturus Therapeutics
$67.59 /

+18.23 (+36.93%)

ARCT Arcturus Therapeutics
$67.59 /

+18.23 (+36.93%)

ARCT Arcturus Therapeutics
$67.59 /

+18.23 (+36.93%)

Initiation
Fly Intel: Top five analyst initiations » 09:56
01/07/21
01/07
09:56
01/07/21
09:56
ARCT

Arcturus Therapeutics

$52.26 /

+2.9 (+5.88%)

, MGTA

Magenta Therapeutics

$8.24 /

+0.34 (+4.30%)

, ARAY

Accuray

$4.95 /

+0.08 (+1.64%)

, NOG

Northern Oil and Gas

$9.89 /

+0.26 (+2.70%)

, KNOP

Knot Offshore Partners

$15.55 /

+0.26 (+1.70%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Arcturus Therapeutics (ARCT) initiated with an Overweight at Wells Fargo. 2. Magenta Therapeutics (MGTA) initiated with a Buy at Mizuho. 3. Accuray (ARAY) initiated with an Outperform at Northland. 4. Northern Oil and Gas (NOG) initiated with a Strong Buy at Raymond James. 5. Knot Offshore Partners (KNOP) initiated with Buy at B. Riley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

MGTA Magenta Therapeutics
$8.24 /

+0.34 (+4.30%)

KNOP Knot Offshore Partners
$15.55 /

+0.26 (+1.70%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

ARAY Accuray
$4.95 /

+0.08 (+1.64%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

01/07/21 Wells Fargo
Arcturus Therapeutics initiated with an Overweight at Wells Fargo
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
MGTA Magenta Therapeutics
$8.24 /

+0.34 (+4.30%)

01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
ARAY Accuray
$4.95 /

+0.08 (+1.64%)

01/07/21 Northland
Accuray initiated with an Outperform at Northland
09/28/20 Lake Street
CMS 'pouring fuel on the fire' for Accuray with APM rule, says Lake Street
09/18/20 Cowen
New CMS model should provide tailwind for Accuray, says Cowen
04/17/20 JPMorgan
Varian Medical price target lowered to $90 from $100 at JPMorgan
NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

01/07/21 Raymond James
Northern Oil and Gas initiated with a Strong Buy at Raymond James
01/07/21 Raymond James
Northern Oil and Gas initiated with a Strong Buy at Raymond James
12/31/20 Truist
Northern Oil and Gas price target raised to $11 from $7 at Truist
10/15/20 Truist
Northern Oil and Gas price target lowered to $10 from $20 at Truist
KNOP Knot Offshore Partners
$15.55 /

+0.26 (+1.70%)

01/07/21 B. Riley Securities
Knot Offshore Partners initiated with Buy, $20 target at B. Riley
01/06/21 B. Riley Securities
KNOT Offshore Partners initiated with a Buy at B. Riley Securities
NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

MGTA Magenta Therapeutics
$8.24 /

+0.34 (+4.30%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

ARAY Accuray
$4.95 /

+0.08 (+1.64%)

  • 08
    Dec
  • 29
    Jul
  • 25
    Jun
  • 16
    Apr
ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

ARAY Accuray
$4.95 /

+0.08 (+1.64%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

Initiation
Arcturus Therapeutics initiated with an Overweight at Wells Fargo » 06:24
01/07/21
01/07
06:24
01/07/21
06:24
ARCT

Arcturus Therapeutics

$49.46 /

+0.59 (+1.21%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough initiated coverage of Arcturus Therapeutics with an Overweight rating and $118 price target. Birchenough believes that Arcturus has validated the potential value and differentiation of its self-amplifying mRNA delivery through novel lipid nanoparticle suspension and is poised for success with its lead mRNA vaccine ARCT-021 and sees a window for ARCT-021 to achieve competitive data with a superior dose form and drive significant value.

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$49.46 /

+0.59 (+1.21%)

ARCT Arcturus Therapeutics
$49.46 /

+0.59 (+1.21%)

12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
12/29/20 Raymond James
Raymond James cuts Arcturus to Market Perform after 'underwhelming' vaccine data
ARCT Arcturus Therapeutics
$49.46 /

+0.59 (+1.21%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
ARCT Arcturus Therapeutics
$49.46 /

+0.59 (+1.21%)

ARCT Arcturus Therapeutics
$49.46 /

+0.59 (+1.21%)

ARCT Arcturus Therapeutics
$49.46 /

+0.59 (+1.21%)

Options
Arcturus Therapeutics call volume above normal and directionally bullish » 13:45
01/04/21
01/04
13:45
01/04/21
13:45
ARCT

Arcturus Therapeutics

$49.93 /

+6.51 (+14.99%)

Bullish option flow…

Bullish option flow detected in Arcturus Therapeutics with 7,870 calls trading, 3x expected, and implied vol increasing almost 5 points to 125.33%. Jan-21 50 calls and Jan-21 75 calls are the most active options, with total volume in those strikes near 2,600 contracts. The Put/Call Ratio is 0.12. Earnings are expected on March 11th.

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$49.93 /

+6.51 (+14.99%)

ARCT Arcturus Therapeutics
$49.93 /

+6.51 (+14.99%)

12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
12/29/20 Raymond James
Raymond James cuts Arcturus to Market Perform after 'underwhelming' vaccine data
ARCT Arcturus Therapeutics
$49.93 /

+6.51 (+14.99%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
ARCT Arcturus Therapeutics
$49.93 /

+6.51 (+14.99%)

ARCT Arcturus Therapeutics
$49.93 /

+6.51 (+14.99%)

On The Fly
Fly Intel: Pre-market Movers » 09:09
01/04/21
01/04
09:09
01/04/21
09:09
TSLA

Tesla

$705.10 /

+10.36 (+1.49%)

, FLIR

FLIR Systems

$43.86 /

+0.02 (+0.05%)

, MGLN

Magellan Health

$82.86 /

+0.36 (+0.44%)

, NCTY

The9

$3.53 /

+0.14 (+4.13%)

, HLF

Herbalife Nutrition

$47.98 /

+0.22 (+0.46%)

, VRAY

ViewRay

$3.82 /

-0.005 (-0.13%)

, ARCT

Arcturus Therapeutics

$43.42 /

-3.34 (-7.14%)

, ALSK

Alaska Communications

$3.71 /

+0.075 (+2.07%)

, GT

Goodyear Tire

$10.91 /

+0.265 (+2.49%)

, GNW

Genworth

$3.80 /

-0.325 (-7.88%)

, AI

C3.ai

$138.81 /

-7.815 (-5.33%)

, TDY

Teledyne

$392.02 /

+0.575 (+0.15%)

, CNC

Centene

$60.04 /

+1.11 (+1.88%)

Check out this morning's…

ShowHide Related Items >><<
VRAY ViewRay
$3.82 /

-0.005 (-0.13%)

TSLA Tesla
$705.10 /

+10.36 (+1.49%)

TDY Teledyne
$392.02 /

+0.575 (+0.15%)

NCTY The9
$3.53 /

+0.14 (+4.13%)

MGLN Magellan Health
$82.86 /

+0.36 (+0.44%)

HLF Herbalife Nutrition
$47.98 /

+0.22 (+0.46%)

GT Goodyear Tire
$10.91 /

+0.265 (+2.49%)

GNW Genworth
$3.80 /

-0.325 (-7.88%)

FLIR FLIR Systems
$43.86 /

+0.02 (+0.05%)

CNC Centene
$60.04 /

+1.11 (+1.88%)

ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

ALSK Alaska Communications
$3.71 /

+0.075 (+2.07%)

AI C3.ai
$138.81 /

-7.815 (-5.33%)

TSLA Tesla
$705.10 /

+10.36 (+1.49%)

01/04/21 Wedbush
Basically hitting 500k goal 'a major feather in the cap' for Tesla, says Wedbush
01/04/21 Oppenheimer
Tesla investors to look for progress on self-driving mode, says Oppenheimer
01/04/21 Deutsche Bank
Tesla price target raised to $705 from $500 at Deutsche Bank
01/04/21 JMP Securities
Tesla Q4 deliveries topped expectations on 'very strong China' data, says JMP
FLIR FLIR Systems
$43.86 /

+0.02 (+0.05%)

08/27/20 Canaccord
FLIR Systems weakness a buying opportunity, says Canaccord
07/16/20 Needham
FLIR Systems price target raised to $55 from $52 at Needham
07/02/20
Fly Intel: Top five analyst initiations
07/02/20 Canaccord
Flir Systems initiated with a Buy at Canaccord
MGLN Magellan Health
$82.86 /

+0.36 (+0.44%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
NCTY The9
$3.53 /

+0.14 (+4.13%)

HLF Herbalife Nutrition
$47.98 /

+0.22 (+0.46%)

12/24/20 Citi
Herbalife Nutrition price target raised to $66 from $63 at Citi
09/11/20 Jefferies
Herbalife, Nu Skin valuation gaps can close as models transform, says Jefferies
06/22/20 Citi
Citi boosts Herbalife target to $63, opens '90 Day Catalyst Watch'
05/08/20 Jefferies
Herbalife Nutrition price target raised to $45 from $40 at Jefferies
VRAY ViewRay
$3.82 /

-0.005 (-0.13%)

11/06/20 Piper Sandler
ViewRay price target raised to $4 from $3.50 at Piper Sandler
10/28/20
Fly Intel: Top five analyst upgrades
10/28/20 B. Riley Securities
ViewRay upgraded to Buy from Neutral at B. Riley Securities
10/07/20 Piper Sandler
ViewRay amended agreement with Siemens favorable, says Piper Sandler
ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
12/29/20 Raymond James
Raymond James cuts Arcturus to Market Perform after 'underwhelming' vaccine data
ALSK Alaska Communications
$3.71 /

+0.075 (+2.07%)

GT Goodyear Tire
$10.91 /

+0.265 (+2.49%)

01/04/21 Nomura
Goodyear Tire downgraded to Reduce from Neutral at Nomura
12/11/20 Morgan Stanley
Goodyear Tire assumed with an Equal Weight at Morgan Stanley
10/22/20 JPMorgan
Goodyear Tire price target raised to $11 from $8 at JPMorgan
10/13/20 Deutsche Bank
Goodyear Tire price target raised to $10 from $9 at Deutsche Bank
GNW Genworth
$3.80 /

-0.325 (-7.88%)

AI C3.ai
$138.81 /

-7.815 (-5.33%)

01/04/21 Wedbush
Wedbush bullish on C3.ai, initiates with an Outperform
01/04/21 Canaccord
C3.ai initiated with a Hold at Canaccord
01/04/21 Morgan Stanley
C3.ai initiated with an Underweight at Morgan Stanley
01/04/21 Deutsche Bank
C3.ai initiated with a Hold at Deutsche Bank
TDY Teledyne
$392.02 /

+0.575 (+0.15%)

10/07/20
Fly Intel: Top five analyst initiations
10/07/20 Goldman Sachs
Teledyne initiated with a Neutral at Goldman Sachs
08/25/20 Wolfe Research
Teledyne initiated with an Outperform at Wolfe Research
07/15/20 Jefferies
Jefferies upgrades Teledyne to Buy, sees Q2 as likely trough
CNC Centene
$60.04 /

+1.11 (+1.88%)

12/22/20 JPMorgan
Latest Georgia polling favors Republicans, says JPMorgan
12/21/20 Deutsche Bank
Centene price target lowered to $77 from $83 at Deutsche Bank
11/16/20 Citi
Citi opens 'negative catalyst watch' on Centene
11/11/20 Piper Sandler
Centene price target raised to $89 from $83 at Piper Sandler
VRAY ViewRay
$3.82 /

-0.005 (-0.13%)

TSLA Tesla
$705.10 /

+10.36 (+1.49%)

TDY Teledyne
$392.02 /

+0.575 (+0.15%)

MGLN Magellan Health
$82.86 /

+0.36 (+0.44%)

HLF Herbalife Nutrition
$47.98 /

+0.22 (+0.46%)

GT Goodyear Tire
$10.91 /

+0.265 (+2.49%)

GNW Genworth
$3.80 /

-0.325 (-7.88%)

FLIR FLIR Systems
$43.86 /

+0.02 (+0.05%)

CNC Centene
$60.04 /

+1.11 (+1.88%)

ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

AI C3.ai
$138.81 /

-7.815 (-5.33%)

  • 08
    Dec
  • 09
    Dec
  • 29
    Jul
  • 16
    Apr
  • 14
    Feb
TSLA Tesla
$705.10 /

+10.36 (+1.49%)

HLF Herbalife Nutrition
$47.98 /

+0.22 (+0.46%)

GNW Genworth
$3.80 /

-0.325 (-7.88%)

CNC Centene
$60.04 /

+1.11 (+1.88%)

ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

TSLA Tesla
$705.10 /

+10.36 (+1.49%)

HLF Herbalife Nutrition
$47.98 /

+0.22 (+0.46%)

GT Goodyear Tire
$10.91 /

+0.265 (+2.49%)

GNW Genworth
$3.80 /

-0.325 (-7.88%)

CNC Centene
$60.04 /

+1.11 (+1.88%)

ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

ALSK Alaska Communications
$3.71 /

+0.075 (+2.07%)

AI C3.ai
$138.81 /

-7.815 (-5.33%)

TSLA Tesla
$705.10 /

+10.36 (+1.49%)

HLF Herbalife Nutrition
$47.98 /

+0.22 (+0.46%)

GT Goodyear Tire
$10.91 /

+0.265 (+2.49%)

GNW Genworth
$3.80 /

-0.325 (-7.88%)

FLIR FLIR Systems
$43.86 /

+0.02 (+0.05%)

CNC Centene
$60.04 /

+1.11 (+1.88%)

AI C3.ai
$138.81 /

-7.815 (-5.33%)

Hot Stocks
Arcturus Therapeutics receives FDA allowance to proceed with ARCT-021 study » 07:12
01/04/21
01/04
07:12
01/04/21
07:12
ARCT

Arcturus Therapeutics

$43.42 /

-3.34 (-7.14%)

Arcturus Therapeutics…

Arcturus Therapeutics announced that the company has received allowance of the investigational new drug, or IND, application from the FDA for the Phase 2 clinical study of its vaccine candidate ARCT-021 following review of data from the Phase 1/2 study. The Phase 2 study will enroll 600 participants, with 450 receiving ARCT-021 and 150 receiving placebo. Both older and younger adult participants will be included. Early interim analyses of safety and immunogenicity will be performed to inform dose selection for a Phase 3 study, which is targeted to start in Q2, if the Phase 2 study is successful.

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
12/29/20 Raymond James
Raymond James cuts Arcturus to Market Perform after 'underwhelming' vaccine data
ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

ARCT Arcturus Therapeutics
$43.42 /

-3.34 (-7.14%)

Recommendations
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg » 07:18
12/31/20
12/31
07:18
12/31/20
07:18
ARCT

Arcturus Therapeutics

$46.76 /

+4.41 (+10.41%)

, MRNA

Moderna

$111.14 /

-3.25 (-2.84%)

, PFE

Pfizer

$36.74 /

-0.31 (-0.84%)

Ladenburg analyst Wangzhi…

Ladenburg analyst Wangzhi Li said that a UK study of 2,826 healthcare and frontline workers with high exposure risk to COVID-19 shows "strong evidence" that T cell response alone in seronegative subjects could achieve complete protection from COVID-19 without antibody response, which the analyst points to as support for the view that there is a "good probability" that Arcturus Therapeutics' (ARCT) ARCT-021 can ultimately achieve "90+% protection efficacy" despite the latest ARCT-021 data update that raised questions about a lower titer of neutralizing antibody response. The analyst, who still sees a good probability for ARCT-021 to achieve efficacy close to that seen with the vaccines from Moderna (MRNA) and Pfizer (PFE), keeps a Buy rating and $123 price target on Arcturus shares.

ShowHide Related Items >><<
PFE Pfizer
$36.74 /

-0.31 (-0.84%)

MRNA Moderna
$111.14 /

-3.25 (-2.84%)

ARCT Arcturus Therapeutics
$46.76 /

+4.41 (+10.41%)

ARCT Arcturus Therapeutics
$46.76 /

+4.41 (+10.41%)

12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
12/29/20 Raymond James
Raymond James cuts Arcturus to Market Perform after 'underwhelming' vaccine data
12/29/20 B. Riley Securities
Arcturus data reaffirm feasibility of pursuing vaccine, says B. Riley
MRNA Moderna
$111.14 /

-3.25 (-2.84%)

12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/24/20 Piper Sandler
Piper calls Inovio's COVID vaccine candidate 'an also-ran' after data published
12/24/20 Morgan Stanley
Morgan Stanley sees greater FY22 COVID vaccine opportunity at McKesson
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
PFE Pfizer
$36.74 /

-0.31 (-0.84%)

12/29/20 Citi
Citi boosts Myovant target to $30 on 'smart deal' with Pfizer
12/29/20 Baird
Baird positive on Myovant Sciences deal announcement with Pfizer
12/28/20 Goldman Sachs
Goldman says 'attractive' Myovant deal with Pfizer improves outlook for Orgovyx
PFE Pfizer
$36.74 /

-0.31 (-0.84%)

MRNA Moderna
$111.14 /

-3.25 (-2.84%)

ARCT Arcturus Therapeutics
$46.76 /

+4.41 (+10.41%)

  • 08
    Dec
  • 29
    Jul
  • 19
    May
  • 16
    Apr
  • 12
    Feb
PFE Pfizer
$36.74 /

-0.31 (-0.84%)

MRNA Moderna
$111.14 /

-3.25 (-2.84%)

ARCT Arcturus Therapeutics
$46.76 /

+4.41 (+10.41%)

PFE Pfizer
$36.74 /

-0.31 (-0.84%)

MRNA Moderna
$111.14 /

-3.25 (-2.84%)

ARCT Arcturus Therapeutics
$46.76 /

+4.41 (+10.41%)

PFE Pfizer
$36.74 /

-0.31 (-0.84%)

MRNA Moderna
$111.14 /

-3.25 (-2.84%)

Recommendations
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform » 11:03
12/30/20
12/30
11:03
12/30/20
11:03
ARCT

Arcturus Therapeutics

$43.05 /

+0.7 (+1.65%)

After Arcturus announced…

After Arcturus announced this morning its selection of a therapeutic candidate, ARCT-032, for the LUNAR-CF program, Piper Sandler analyst Yasmeen Rahimi noted that "bears may view this morning's announcement as a distraction from ARCT-021's COVID-19 program." However, Rahimi thinks the market has been "overreacting" to the neutralizing titer data from ARCT-021's Phase 1 update and continues to "strongly believe" in the company's mRNA technology platform, the analyst tells investors. Rahimi has an Overweight rating and $140 price target on Arcturus shares.

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$43.05 /

+0.7 (+1.65%)

ARCT Arcturus Therapeutics
$43.05 /

+0.7 (+1.65%)

12/29/20
Fly Intel: Top five analyst calls
12/29/20 Raymond James
Raymond James cuts Arcturus to Market Perform after 'underwhelming' vaccine data
12/29/20 B. Riley Securities
Arcturus data reaffirm feasibility of pursuing vaccine, says B. Riley
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
ARCT Arcturus Therapeutics
$43.05 /

+0.7 (+1.65%)

  • 08
    Dec
  • 29
    Jul
  • 16
    Apr
ARCT Arcturus Therapeutics
$43.05 /

+0.7 (+1.65%)

ARCT Arcturus Therapeutics
$43.05 /

+0.7 (+1.65%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.